Significance of Serum Relaxin in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease

Abstract

 Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. The aim of the work is to evaluate significance of serum relaxin in diabetic and non-diabetic patients with chronic kidney disease. 60 subjects aged from (18years to 60 years) in internal medicine department at Tanta University hospital (outpatient –inward). This study was carried out from between March 2020 to March 2021. There was insignificant difference between groups according to age There was an inverse significant correlation between serum relaxin level and HBA1C in group 2 .but not in group 3. There was an inverse significant correlation between serum relaxin level and creatinine in group 2 .and in group 3. the best cut of level of relaxin hormone in discriminating normal individuals fron CKD patients was 150 ng/dl with an area under the curve(AUC) of 0,988 yeilding sensitivity of 93%, specifity of 95% , positive predictive value (PPV) 97%, negative predictive value(NPV) 86% and accuracy of 93%. Serum RLX levels are significantly lower in patients with CKD than healthy subjects. Furthermore, when compared to non-diabetic patients, they are much lower in diabetic patients. This research suggests that RLX could be a useful therapeutic option for diabetic nephropathy patients with developed fibrosis. RLX has a high safety profile, with potentially fewer adverse effects than conventional treatments because it is a naturally occurring physiological hormone. However, further effort is required.